MX2016016744A - Inhibidores de ezh2 para tratar linfomas. - Google Patents
Inhibidores de ezh2 para tratar linfomas.Info
- Publication number
- MX2016016744A MX2016016744A MX2016016744A MX2016016744A MX2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A
- Authority
- MX
- Mexico
- Prior art keywords
- ezh2 inhibitors
- ezh2
- treating lymphoma
- subject
- present
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 206010025323 Lymphomas Diseases 0.000 title 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 3
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 3
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950004774 tazemetostat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención se refiere a métodos para tratar el cáncer mediante la administración de un inhibidor de EZH2 o de una composición farmacéutica del mismo al sujeto que lo necesite. Las presentes reivindicaciones definen métodos para tratar subtipos específicos de linfoma no Hodgkin que comprenden la administración a un sujeto de inhibidores de EZH2. Los inhibidores de EZH2 preferidos incluyen tazemetostat (EPZ6438 E7438) y otros compuestos. También se definen cantidades y regímenes de dosificación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013522P | 2014-06-17 | 2014-06-17 | |
| US201462036265P | 2014-08-12 | 2014-08-12 | |
| PCT/US2015/036310 WO2015195848A1 (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016016744A true MX2016016744A (es) | 2017-11-30 |
Family
ID=54936086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007651A MX2021007651A (es) | 2014-06-17 | 2015-06-17 | Inhibidores de ezh2 para tratar linfomas. |
| MX2016016744A MX2016016744A (es) | 2014-06-17 | 2015-06-17 | Inhibidores de ezh2 para tratar linfomas. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007651A MX2021007651A (es) | 2014-06-17 | 2015-06-17 | Inhibidores de ezh2 para tratar linfomas. |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10166238B2 (es) |
| EP (2) | EP4252851A3 (es) |
| JP (1) | JP6779793B2 (es) |
| KR (2) | KR20230031963A (es) |
| CN (2) | CN113289022A (es) |
| AU (3) | AU2015277139A1 (es) |
| BR (1) | BR112016029492A2 (es) |
| CA (1) | CA2952074C (es) |
| DK (1) | DK3157527T3 (es) |
| EA (1) | EA038337B1 (es) |
| ES (1) | ES2948442T3 (es) |
| FI (1) | FI3157527T3 (es) |
| HU (1) | HUE062158T2 (es) |
| IL (3) | IL309539A (es) |
| LT (1) | LT3157527T (es) |
| MX (2) | MX2021007651A (es) |
| PL (1) | PL3157527T3 (es) |
| PT (1) | PT3157527T (es) |
| SG (2) | SG10201811128RA (es) |
| SI (1) | SI3157527T1 (es) |
| WO (1) | WO2015195848A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| KR20210117347A (ko) | 2013-12-06 | 2021-09-28 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| ES2948442T3 (es) * | 2014-06-17 | 2023-09-12 | Epizyme Inc | Inhibidores de EZH2 para el tratamiento de linfoma |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| KR102644844B1 (ko) * | 2014-11-17 | 2024-03-07 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| SG10201902664RA (en) | 2015-04-20 | 2019-04-29 | Epizyme Inc | Combination therapy for treating cancer |
| MX2017015938A (es) * | 2015-06-10 | 2018-11-09 | Epizyme Inc | Inhibidores de ezh2 para el tratar linfomas. |
| IL307260A (en) | 2015-08-24 | 2023-11-01 | Epizyme Inc | A method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| JP2019503391A (ja) * | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| JP2019521988A (ja) * | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| AU2018210141A1 (en) * | 2017-01-20 | 2019-08-29 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US20210161883A1 (en) * | 2017-07-10 | 2021-06-03 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitor-induced gene expression |
| JP7399079B2 (ja) | 2017-09-05 | 2023-12-15 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP2614369B1 (en) | 2010-09-10 | 2016-02-03 | Epizyme, Inc. | Method for determining the suitability of inhibitors of human ezh2 in treatment |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| RU2014117632A (ru) | 2011-09-30 | 2015-11-10 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения злокачественной опухоли |
| HUE042271T2 (hu) * | 2012-03-12 | 2019-06-28 | Epizyme Inc | Emberi EZH2 inhibitorai és azok alkalmazási eljárásai |
| CN108358899B (zh) | 2012-04-13 | 2021-07-27 | Epizyme股份有限公司 | 人类组蛋白甲基转移酶ezh2抑制剂的盐形式 |
| CA2870010C (en) | 2012-04-13 | 2023-02-21 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
| US9006242B2 (en) | 2012-10-15 | 2015-04-14 | Epizyme, Inc. | Substituted benzene compounds |
| US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| RS58023B2 (sr) * | 2012-11-01 | 2021-12-31 | Infinity Pharmaceuticals Inc | Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza |
| WO2014100080A1 (en) | 2012-12-19 | 2014-06-26 | Glaxosmithkline Llc | Combination |
| US9701666B2 (en) | 2012-12-21 | 2017-07-11 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2935214B1 (en) | 2012-12-21 | 2019-02-20 | Epizyme, Inc. | 1,4-pyridone compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5 |
| EP2970281A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BENZENE COMPOUNDS |
| US20160113932A1 (en) * | 2013-05-30 | 2016-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| ES2705573T3 (es) | 2013-10-09 | 2019-03-26 | Hoffmann La Roche | Procedimientos y composiciones para detectar mutaciones en el gen EZH2 humano |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| AU2014337121A1 (en) | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| KR20210117347A (ko) | 2013-12-06 | 2021-09-28 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| ES2948442T3 (es) | 2014-06-17 | 2023-09-12 | Epizyme Inc | Inhibidores de EZH2 para el tratamiento de linfoma |
| KR20170098808A (ko) | 2014-11-06 | 2017-08-30 | 다나-파버 캔서 인스티튜트 인크. | 이식편 대 숙주 질환 (gvhd)에 대한 염색질 구조를 조정하는 조성물의 용도 |
| KR102644844B1 (ko) | 2014-11-17 | 2024-03-07 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| JP6544507B2 (ja) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | ヘッドアップディスプレイ装置 |
| MX2017015938A (es) | 2015-06-10 | 2018-11-09 | Epizyme Inc | Inhibidores de ezh2 para el tratar linfomas. |
| KR20170095656A (ko) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | 방열구조를 갖는 세탁기 |
-
2015
- 2015-06-17 ES ES15809540T patent/ES2948442T3/es active Active
- 2015-06-17 IL IL309539A patent/IL309539A/en unknown
- 2015-06-17 SI SI201531951T patent/SI3157527T1/sl unknown
- 2015-06-17 MX MX2021007651A patent/MX2021007651A/es unknown
- 2015-06-17 KR KR1020237004113A patent/KR20230031963A/ko not_active Application Discontinuation
- 2015-06-17 LT LTEPPCT/US2015/036310T patent/LT3157527T/lt unknown
- 2015-06-17 SG SG10201811128RA patent/SG10201811128RA/en unknown
- 2015-06-17 US US15/319,535 patent/US10166238B2/en active Active
- 2015-06-17 EP EP23174369.1A patent/EP4252851A3/en active Pending
- 2015-06-17 EP EP15809540.6A patent/EP3157527B1/en active Active
- 2015-06-17 HU HUE15809540A patent/HUE062158T2/hu unknown
- 2015-06-17 BR BR112016029492A patent/BR112016029492A2/pt not_active Application Discontinuation
- 2015-06-17 CN CN202110532717.0A patent/CN113289022A/zh active Pending
- 2015-06-17 CN CN201580036258.XA patent/CN106999498B/zh active Active
- 2015-06-17 KR KR1020177000760A patent/KR102497728B1/ko active IP Right Grant
- 2015-06-17 EA EA201692285A patent/EA038337B1/ru unknown
- 2015-06-17 PT PT158095406T patent/PT3157527T/pt unknown
- 2015-06-17 CA CA2952074A patent/CA2952074C/en active Active
- 2015-06-17 IL IL285201A patent/IL285201B1/en unknown
- 2015-06-17 DK DK15809540.6T patent/DK3157527T3/da active
- 2015-06-17 JP JP2016573564A patent/JP6779793B2/ja active Active
- 2015-06-17 FI FIEP15809540.6T patent/FI3157527T3/fi active
- 2015-06-17 PL PL15809540.6T patent/PL3157527T3/pl unknown
- 2015-06-17 SG SG11201610273VA patent/SG11201610273VA/en unknown
- 2015-06-17 AU AU2015277139A patent/AU2015277139A1/en not_active Abandoned
- 2015-06-17 WO PCT/US2015/036310 patent/WO2015195848A1/en active Application Filing
- 2015-06-17 MX MX2016016744A patent/MX2016016744A/es unknown
-
2016
- 2016-12-07 IL IL249438A patent/IL249438A0/en unknown
-
2018
- 2018-11-06 US US16/181,747 patent/US20190175604A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,835 patent/US20200022987A1/en not_active Abandoned
-
2020
- 2020-03-04 US US16/808,513 patent/US11642347B2/en active Active
- 2020-09-28 AU AU2020244382A patent/AU2020244382B2/en active Active
-
2022
- 2022-11-03 AU AU2022263523A patent/AU2022263523A1/en active Pending
-
2023
- 2023-03-23 US US18/188,716 patent/US20240058348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016744A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| PH12016502355B1 (en) | Pharmaceutical composition | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| MX2016016039A (es) | Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización.. | |
| TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2019039937A8 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER |